Quick Login
CLOSE X
FRR FAMILY
FRR BOSS NEW
TRAINEE MILLIONAIRE
FRR FOREX
FRRBOSS SHAREPRO
FRR RE-KYC
Equity
Home/ Are You A Trader/  Market Info/  Company Profile/  Quarterly Results

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE2517.4061.4 (+2.5 %)
PREV CLOSE (Rs.) 2456.00
OPEN PRICE (Rs.) 2479.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 19900
TODAY'S LOW / HIGH (Rs.)2432.40 2536.85
52 WK LOW / HIGH (Rs.)1794 2483.3
NSE2515.0055 (+2.24 %)
PREV CLOSE( Rs. ) 2460.00
OPEN PRICE (Rs.) 2460.00
BID PRICE (QTY) 2515.00 (925)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 807816
TODAY'S LOW / HIGH(Rs.) 2431.70 2537.60
52 WK LOW / HIGH (Rs.)1792.6 2484

Quarterly Results

Type
Quarters
GO
Select year
(Rs.in Million)
Particulars
Jun 2026
Mar 2026
Dec 2025
Sep 2025
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
40184.83
37705.86
39006.15
60468.70
Total Expenditure
32136.87
30079.89
30308.66
36873.19
PBIDT (Excl OI)
8047.96
7625.97
8697.49
23595.51
Other Income
657.64
1890.83
444.65
2006.29
Operating Profit
8705.60
9516.80
9142.14
25601.80
Interest
539.97
426.04
414.32
664.63
Exceptional Items
0.00
-3733.99
-1843.37
-13851.16
PBDT
8165.63
5356.77
6884.45
11086.01
Depreciation
1731.74
1479.09
1544.46
1412.00
Profit Before Tax
6433.89
3877.68
5339.99
9674.01
Tax
1605.61
864.49
1307.71
3569.69
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
4828.28
3013.19
4032.28
6104.32
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
4828.28
3013.19
4032.28
6104.32
Minority Interest
0.96
0.95
-0.15
-0.79
Shares of Associates
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
4829.24
3014.14
4032.13
6103.53
Equity Capital
282.20
282.20
282.20
282.20
Face Value (IN RS)
1.00
1.00
1.00
1.00
Reserves
NA
NA
NA
NA
Calculated EPS
17.11
10.68
14.29
21.63
Calculated EPS (Annualised)
68.45
42.72
57.15
86.51
No of Public Share Holdings
150543487.00
150548127.00
150552417.00
150567872.00
% of Public Share Holdings
53.35
53.35
53.35
53.35
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
20.03
20.22
22.30
39.02
PBIDTM%
21.66
25.24
23.44
42.34
PBDTM%
20.32
14.21
17.65
18.33
PBTM%
16.01
10.28
13.69
16.00
PATM%
12.02
7.99
10.34
10.10
 
Notes
Notes
Notes
Notes
Attention Investors KYC ASBA NOMINATION

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Privacy | Disclaimer | Copyright | Terms & Conditions | Investor Grievance | Advisory for Investor | Investor Charter And Complaints | Investor SEBI Scores |
Regulatory Information | Documents in Vernacular Languages | CDSL E-Voting | Link Pan and Aadhaar | Fund Transfer | Segregation And Monitoring Of Collateral At Client Level |
Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links
BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015
Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.
© 2015 FRR Shares. All Rights Reserved | Designed, Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
close X

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :
Assamese Bengali Gujarati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu

NOTE : " This document is a translated version of the client registration documents in English and is being provided in vernacular language to facilitate better understanding by the investors. In case of any ambiguity, the contents of the English version would prevail. "